• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

PHAR

Partnership for Health Analytic Research

  • Services
    • Real World Data: Secondary Data Analysis
    • Real World Data: Primary Data Collection
    • Evidence Synthesis
  • Publications
  • Clients
  • Team
  • News
  • Contact

Primary Sidebar

News Categories

  • Uncategorized
  • Presentations & Events
  • Awards & Recognition
  • Publications
  • News & Announcements

Archive

  • 2023
  • 2022
  • 2021
  • 2020

PHAR Publishes New Findings on Healthcare Resource Utilization and Costs in AL Amyloidosis

A study done by PHAR in partnership with Prothena Biosciences Inc., was recently published in the Journal of Comparative Effectiveness Research. The study estimated the healthcare utilization and costs in amyloid light-chain (AL) amyloidosis. The authors identified AL amyloidosis patients in claims data from 2007 to 2015 and reported inpatient hospitalizations, emergency department visits, non-ED outpatient service visits, and pharmacy utilization. The study found that the general prescribing practices changed over time, with the use of bortezomib increasing and the use of melphalan decreasing. Healthcare utilization and costs decreased between the first and second year after diagnosis. The full text of the study can be read here.

July 10, 2018 | Publications

Partnership for Health Analytic Research

Beverly Hills
Cambridge
San Francisco
info@pharllc.com
310.858.9555
pharllc.com
  • Employment
  • Contact
  • Privacy Policy
Design by Studio Rainwater
© PHAR 2023